Genzyme Renagel Margins To Exceed 70% Following Manufacturing Upgrades
Executive Summary
Genzyme expects Renagel gross margins to exceed 70% by year-end as a result of manufacturing process upgrades for the phosphate binder
You may also be interested in...
Genzyme Renagel Inventory Stable By 2003; Wholesaler Agreements Planned
Genzyme will use formal agreements with wholesalers to draw down excess Renagel inventory levels by the beginning of 2003, Renagel General Manager John Butler said during a conference call to announce revised earnings estimates Sept. 16
Genzyme Renagel Inventory Stable By 2003; Wholesaler Agreements Planned
Genzyme will use formal agreements with wholesalers to draw down excess Renagel inventory levels by the beginning of 2003, Renagel General Manager John Butler said during a conference call to announce revised earnings estimates Sept. 16
Genzyme Renagel Kidney Disease Trials Focus On Moderate/Severe Patients
Genzyme's Renagel development program in chronic kidney disease will initially focus on moderate to severe patients who are under the care of a nephrologist